(CNN) – The vaccine against Novavax’s covid-19 is 89% effective in a clinical trial conducted in the United Kingdom and may offer protection against some variants of the new coronavirus, announced the biotechnology consulting firm.
Novavax said these juveniles found that their vaccine had an 95.6% efficacy against the original new coronavirus and an 85.6% efficacy versus the first-identified variant in the United Kingdom, known as B.1,1.7, following the results of a Phase 3 trial conducted in the United Kingdom. The study included efficacy estimates for each of the PCR samples performed in variants of 56 covid-19 cases in the assay.
Per the vacancy appears less effective against a first-identified variant in South Africa. The injection showed a 60% efficacy between VIH individuals in a separate Phase 2b study conducted in this country. The efficiency is reduced to 49.4% when people are included with VIH.
Novavax says it plans to launch a caravan specifically for the variant identified in South Africa. The company also says that it has started working on a new version of the vehicle that will be used as a vehicle for recovery against emerging diseases. His goal is to start the clinical trials of this year in the second quarter of this year.
The vaccine attempts against Novavax’s covid-19
The company’s vaccine, known as NVX-CoV2373, “is the first vaccine to be demonstrated without a single clinical efficacy against covid-19, as well as a significant clinical efficacy against renaissance variants emerging from the United Kingdom and South Africa” Stanley , President of the Executive of Novavax, in the announcement. “NVX-CoV2373 has the potential to unravel an important issue in the solution to this global public health crisis.”
According to the South African tax, “the 60% reduction in the contraindication of enrollment by covid-19 in persons evacuated from South Africans will reduce the value of this vaccine in order to prevent the enumeration of the alternative which is particularly prevalent and which is is spreading to the world level », says Shabir Maddi, head of the Novavax vaccine investigation team against covid-19 in South Africa
“This is the first vaccine against covid-19 to now have objective evidence of protecting against the variant that dominates in South Africa,” said Maddi.
The Prime Minister of Gran Bretaña, Boris Johnson, welcomed the results of the British debate, praised the “good news” that the vacancy candidate had demonstrated and expressed his gratitude to “all the willfuls that are possible in these results” a tuit.
“Our drug regulator will now evaluate the vaccine, which will be manufactured in Teesside. If it is approved, we will have 60 million doses of pedophilia, “he said.
Now, the United Kingdom’s inoculation program has seen more than 7.4 million people receive the first dose of a vaccine against the coronavirus, according to the latest figures from Gobierno. Two vacancies, from Pfizer / BioNTech and Oxford / AstraZeneca, are currently in the national level. The Moderna vacuna also received red light.
Novavax is also currently undergoing a Phase 3 clinical study in the United States and Mexico and a Phase 1/2 continuation in the United States and Australia, which will take place as soon as the first trimester principles of 2021.